Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 215

1.

Clinical outcomes of pallidal deep brain stimulation for dystonia implanted using intraoperative MRI.

Sharma VD, Bezchlibnyk YB, Isbaine F, Naik KB, Cheng J, Gale JT, Miocinovic S, Buetefisch C, Factor SA, Willie JT, Boulis NM, Wichmann T, DeLong MR, Gross RE.

J Neurosurg. 2019 Oct 11:1-13. doi: 10.3171/2019.6.JNS19548. [Epub ahead of print]

PMID:
31604331
2.

Lurasidone-Induced Tardive Syndrome.

Tripathi R, Reich SG, Scorr L, Guardiani E, Factor SA.

Mov Disord Clin Pract. 2019 Jul 24;6(7):601-604. doi: 10.1002/mdc3.12812. eCollection 2019 Sep.

PMID:
31538095
3.

Lower Limb Rigidity Is Associated with Frequent Falls in Parkinson's Disease.

McKay JL, Hackney ME, Factor SA, Ting LH.

Mov Disord Clin Pract. 2019 Jun 6;6(6):446-451. doi: 10.1002/mdc3.12784. eCollection 2019 Jul.

PMID:
31392245
4.

Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia.

Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Woods SW, Bega D, LeDoux MS, Shprecher DR, Anderson KE.

J Neurol Neurosurg Psychiatry. 2019 Jul 10. pii: jnnp-2018-319918. doi: 10.1136/jnnp-2018-319918. [Epub ahead of print]

5.

Recent developments in drug-induced movement disorders: a mixed picture.

Factor SA, Burkhard PR, Caroff S, Friedman JH, Marras C, Tinazzi M, Comella CL.

Lancet Neurol. 2019 Sep;18(9):880-890. doi: 10.1016/S1474-4422(19)30152-8. Epub 2019 Jul 3. Review.

PMID:
31279747
6.

46 Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-label Extension Study.

Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Woods SW, LeDoux MS, Shprecher DR, Anderson KE.

CNS Spectr. 2019 Feb;24(1):201. doi: 10.1017/S1092852919000397.

PMID:
30859974
7.

45 Long-term Treatment with Deutetrabenazine Is Associated with Continued Improvement in Tardive Dyskinesia: Results from an Open-label Extension Study.

Hauser RA, Fernandez HH, Stamler D, Davis MD, Factor SA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Woods SW, LeDoux MS, Shprecher DR, Anderson KE.

CNS Spectr. 2019 Feb;24(1):200-201. doi: 10.1017/S1092852919000385.

PMID:
30859973
8.

Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications.

Espay AJ, Guskey MT, Norton JC, Coate B, Vizcarra JA, Ballard C, Factor SA, Friedman JH, Lang AE, Larsen NJ, Andersson C, Fredericks D, Weintraub D.

Mov Disord. 2018 Nov;33(11):1769-1776. doi: 10.1002/mds.27488. Epub 2018 Nov 2.

9.

Plasticity-related gene 3 (LPPR1) and age at diagnosis of Parkinson disease.

Wallen ZD, Chen H, Hill-Burns EM, Factor SA, Zabetian CP, Payami H.

Neurol Genet. 2018 Oct 5;4(5):e271. doi: 10.1212/NXG.0000000000000271. eCollection 2018 Oct.

10.

Camptocormia: a consensus for grading on a curve.

Factor SA.

Parkinsonism Relat Disord. 2018 Jul;52:6. doi: 10.1016/j.parkreldis.2018.06.023. No abstract available.

PMID:
29937101
11.

Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson's Disease.

Houser MC, Chang J, Factor SA, Molho ES, Zabetian CP, Hill-Burns EM, Payami H, Hertzberg VS, Tansey MG.

Mov Disord. 2018 May;33(5):793-804. doi: 10.1002/mds.27326. Epub 2018 Mar 23.

12.

Pilot Single-Blind Trial of AbobotulinumtoxinA in Oromandibular Dystonia.

Scorr LM, Silver MR, Hanfelt J, Sperin E, Freeman A, Jinnah HA, Factor SA.

Neurotherapeutics. 2018 Apr;15(2):452-458. doi: 10.1007/s13311-018-0620-9.

13.

VMAT2 inhibitors for the treatment of tardive dyskinesia.

Scorr LM, Factor SA.

J Neurol Sci. 2018 Jun 15;389:43-47. doi: 10.1016/j.jns.2018.02.006. Epub 2018 Feb 5. Review.

PMID:
29433808
14.

Saccades in progressive supranuclear palsy - maladapted, irregular, curved, and slow.

Shaikh AG, Factor SA, Juncos J.

Mov Disord Clin Pract. 2017 Sep-Oct;4(5):671-681. doi: 10.1002/mdc3.12491. Epub 2017 Aug 11.

15.

The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study.

Factor SA, Remington G, Comella CL, Correll CU, Burke J, Jimenez R, Liang GS, O'Brien CF.

J Clin Psychiatry. 2017 Nov/Dec;78(9):1344-1350. doi: 10.4088/JCP.17m11777.

16.

Affective Correlates of Psychosis in Parkinson's Disease.

Factor SA, Scullin MK, Freeman A, Bliwise DL, McDonald WM, Goldstein FC.

Mov Disord Clin Pract. 2017 Mar-Apr;4(2):225-230. doi: 10.1002/mdc3.12381. Epub 2016 Jun 16.

17.

The role of neurotransmitters in the development of Parkinson's disease-related psychosis.

Factor SA, McDonald WM, Goldstein FC.

Eur J Neurol. 2017 Oct;24(10):1244-1254. doi: 10.1111/ene.13376. Epub 2017 Jul 31. Review.

PMID:
28758318
18.

Phosphodiesterase 4: Rethinking cognition in Parkinson disease.

Jacova C, Factor SA.

Neurology. 2017 Aug 8;89(6):530-531. doi: 10.1212/WNL.0000000000004221. Epub 2017 Jul 12. No abstract available.

PMID:
28701498
19.

Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.

Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojärvi J, Jarskog LF, Jimenez-Shahed J, Kumar R, McEvoy JP, Ochudlo S, Ondo WG, Fernandez HH.

Lancet Psychiatry. 2017 Aug;4(8):595-604. doi: 10.1016/S2215-0366(17)30236-5. Epub 2017 Jun 28.

PMID:
28668671
20.

LRRK2 levels in immune cells are increased in Parkinson's disease.

Cook DA, Kannarkat GT, Cintron AF, Butkovich LM, Fraser KB, Chang J, Grigoryan N, Factor SA, West AB, Boss JM, Tansey MG.

NPJ Parkinsons Dis. 2017 Mar 28;3:11. doi: 10.1038/s41531-017-0010-8. eCollection 2017.

21.

A Comprehensive Approach to Care in Parkinson's Disease Adds Quality to the Current Gold Standard.

Vaughan CP, Prizer LP, Vandenberg AE, Goldstein FC, Trotti LM, Hermida AP, Factor SA.

Mov Disord Clin Pract. 2017 Jun 15;4(5):743-749. doi: 10.1002/mdc3.12508. eCollection 2017 Sep-Oct.

22.

Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease.

Mata IF, Johnson CO, Leverenz JB, Weintraub D, Trojanowski JQ, Van Deerlin VM, Ritz B, Rausch R, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson-Hiller AL, Espay AJ, Revilla FJ, Devoto J, Yearout D, Hu SC, Cholerton BA, Montine TJ, Edwards KL, Zabetian CP.

Neurobiol Aging. 2017 Aug;56:211.e1-211.e7. doi: 10.1016/j.neurobiolaging.2017.04.009. Epub 2017 Apr 20.

23.

Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study.

Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Meltzer HY, Woods SW, Bega D, LeDoux MS, Shprecher DR, Davis C, Davis MD, Stamler D, Anderson KE.

Neurology. 2017 May 23;88(21):2003-2010. doi: 10.1212/WNL.0000000000003960. Epub 2017 Apr 26.

24.

Disentangling Stigma from Functional Neurological Disorders: Conference Report and Roadmap for the Future.

Rommelfanger KS, Factor SA, LaRoche S, Rosen P, Young R, Rapaport MH.

Front Neurol. 2017 Mar 29;8:106. doi: 10.3389/fneur.2017.00106. eCollection 2017.

25.

Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.

Fox SH, Metman LV, Nutt JG, Brodsky M, Factor SA, Lang AE, Pope LE, Knowles N, Siffert J.

Mov Disord. 2017 Jun;32(6):893-903. doi: 10.1002/mds.26976. Epub 2017 Mar 30.

PMID:
28370447
26.

KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.

Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang GS, O'Brien CF.

Am J Psychiatry. 2017 May 1;174(5):476-484. doi: 10.1176/appi.ajp.2017.16091037. Epub 2017 Mar 21.

PMID:
28320223
27.

In vivo detection of lateral-ventral tier nigral degeneration in Parkinson's disease.

Huddleston DE, Langley J, Sedlacik J, Boelmans K, Factor SA, Hu XP.

Hum Brain Mapp. 2017 May;38(5):2627-2634. doi: 10.1002/hbm.23547. Epub 2017 Feb 27.

28.

Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome.

Hill-Burns EM, Debelius JW, Morton JT, Wissemann WT, Lewis MR, Wallen ZD, Peddada SD, Factor SA, Molho E, Zabetian CP, Knight R, Payami H.

Mov Disord. 2017 May;32(5):739-749. doi: 10.1002/mds.26942. Epub 2017 Feb 14.

29.

Psychodynamic Psychotherapy for Functional (Psychogenic) Movement Disorders.

Sharma VD, Jones R, Factor SA.

J Mov Disord. 2017 Jan;10(1):40-44. doi: 10.14802/jmd.16038. Epub 2016 Dec 27.

30.

A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.

McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K, Ross C, Shoulson I, Gilbert P, Mallonee WM, Guttman M, Wojcieszek J, Kumar R, LeDoux MS, Jenkins M, Rosas HD, Nance M, Biglan K, Como P, Dubinsky RM, Shannon KM, O'Suilleabhain P, Chou K, Walker F, Martin W, Wheelock VL, McCusker E, Jankovic J, Singer C, Sanchez-Ramos J, Scott B, Suchowersky O, Factor SA, Higgins DS Jr, Molho E, Revilla F, Caviness JN, Friedman JH, Perlmutter JS, Feigin A, Anderson K, Rodriguez R, McFarland NR, Margolis RL, Farbman ES, Raymond LA, Suski V, Kostyk S, Colcher A, Seeberger L, Epping E, Esmail S, Diaz N, Fung WL, Diamond A, Frank S, Hanna P, Hermanowicz N, Dure LS, Cudkowicz M; Huntington Study Group 2CARE Investigators and Coordinators.

Neurology. 2017 Jan 10;88(2):152-159. doi: 10.1212/WNL.0000000000003478. Epub 2016 Dec 2.

31.

A Functional Magnetic Resonance Imaging Study of Head Movements in Cervical Dystonia.

Prudente CN, Stilla R, Singh S, Buetefisch C, Evatt M, Factor SA, Freeman A, Hu XP, Hess EJ, Sathian K, Jinnah HA.

Front Neurol. 2016 Nov 15;7:201. eCollection 2016.

32.

Propranolol therapy for Tardive dyskinesia: A retrospective examination.

Hatcher-Martin JM, Armstrong KA, Scorr LM, Factor SA.

Parkinsonism Relat Disord. 2016 Nov;32:124-126. doi: 10.1016/j.parkreldis.2016.09.004. Epub 2016 Sep 6.

PMID:
27622970
33.

Physiology of freezing of gait.

Snijders AH, Takakusaki K, Debu B, Lozano AM, Krishna V, Fasano A, Aziz TZ, Papa SM, Factor SA, Hallett M.

Ann Neurol. 2016 Nov;80(5):644-659. doi: 10.1002/ana.24778. Epub 2016 Oct 7. Review.

PMID:
27649270
34.

A case of lithium-induced parkinsonism presenting with typical motor symptoms of Parkinson's disease in a bipolar patient.

Hermida AP, Janjua AU, Glass OM, Vaughan CP, Goldstein F, Trotti LM, Factor SA.

Int Psychogeriatr. 2016 Dec;28(12):2101-2104. Epub 2016 Aug 12.

PMID:
27517671
35.

Identification of genetic modifiers of age-at-onset for familial Parkinson's disease.

Hill-Burns EM, Ross OA, Wissemann WT, Soto-Ortolaza AI, Zareparsi S, Siuda J, Lynch T, Wszolek ZK, Silburn PA, Mellick GD, Ritz B, Scherzer CR, Zabetian CP, Factor SA, Breheny PJ, Payami H.

Hum Mol Genet. 2016 Sep 1;25(17):3849-3862. doi: 10.1093/hmg/ddw206. Epub 2016 Jul 11.

36.

Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.

Huntington Study Group, Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D, O'Neill C, Vaughan C, Goldstein J, Herzog M, Snively V, Whaley J, Wong C, Suter G, Jankovic J, Jimenez-Shahed J, Hunter C, Claassen DO, Roman OC, Sung V, Smith J, Janicki S, Clouse R, Saint-Hilaire M, Hohler A, Turpin D, James RC, Rodriguez R, Rizer K, Anderson KE, Heller H, Carlson A, Criswell S, Racette BA, Revilla FJ, Nucifora F Jr, Margolis RL, Ong M, Mendis T, Mendis N, Singer C, Quesada M, Paulsen JS, Brashers-Krug T, Miller A, Kerr J, Dubinsky RM, Gray C, Factor SA, Sperin E, Molho E, Eglow M, Evans S, Kumar R, Reeves C, Samii A, Chouinard S, Beland M, Scott BL, Hickey PT, Esmail S, Fung WL, Gibbons C, Qi L, Colcher A, Hackmyer C, McGarry A, Klos K, Gudesblatt M, Fafard L, Graffitti L, Schneider DP, Dhall R, Wojcieszek JM, LaFaver K, Duker A, Neefus E, Wilson-Perez H, Shprecher D, Wall P, Blindauer KA, Wheeler L, Boyd JT, Houston E, Farbman ES, Agarwal P, Eberly SW, Watts A, Tariot PN, Feigin A, Evans S, Beck C, Orme C, Edicola J, Christopher E.

JAMA. 2016 Jul 5;316(1):40-50. doi: 10.1001/jama.2016.8655.

37.

The "shirt collar sign" of cervical dystonia.

Silver MR, Hanfelt J, Factor SA.

Int J Neurosci. 2017 May;127(5):466-468. doi: 10.1080/00207454.2016.1188815. Epub 2016 Jun 2.

PMID:
27245470
38.

Freezing of gait: A rare delayed complication of whole brain radiation.

Hatcher-Martin JM, Factor SA.

Parkinsonism Relat Disord. 2016 Aug;29:129-30. doi: 10.1016/j.parkreldis.2016.05.002. Epub 2016 May 3. No abstract available.

PMID:
27194005
39.

Quality improvement in neurology: Parkinson disease update quality measurement set: Executive summary.

Factor SA, Bennett A, Hohler AD, Wang D, Miyasaki JM.

Neurology. 2016 Jun 14;86(24):2278-83. doi: 10.1212/WNL.0000000000002670. Epub 2016 May 11. No abstract available.

40.

Freezing of gait that disappears: Should there be rest before rehab?

Factor SA, Hatcher-Martin JM, Morse AS, Nocera JR, Revuelta GJ.

Parkinsonism Relat Disord. 2016 Jul;28:169-70. doi: 10.1016/j.parkreldis.2016.04.010. Epub 2016 Apr 13. No abstract available.

41.

Diffusion tensor imaging of the substantia nigra in Parkinson's disease revisited.

Langley J, Huddleston DE, Merritt M, Chen X, McMurray R, Silver M, Factor SA, Hu X.

Hum Brain Mapp. 2016 Jul;37(7):2547-56. doi: 10.1002/hbm.23192. Epub 2016 Mar 29.

42.

Clinimetric testing of the comprehensive cervical dystonia rating scale.

Comella CL, Perlmutter JS, Jinnah HA, Waliczek TA, Rosen AR, Galpern WR, Adler CA, Barbano RL, Factor SA, Goetz CG, Jankovic J, Reich SG, Rodriguez RL, Severt WL, Zurowski M, Fox SH, Stebbins GT.

Mov Disord. 2016 Apr;31(4):563-9. doi: 10.1002/mds.26534. Epub 2016 Mar 12.

43.

Ocular palatal tremor plus dystonia - new syndromic association.

Shaikh AG, Ghasia FF, DeLong MR, Jinnah HA, Freeman A, Factor SA.

Mov Disord Clin Pract. 2015 Sep 1;2(3):267-270. Epub 2015 Jun 17.

44.

The RAB39B p.G192R mutation causes X-linked dominant Parkinson's disease.

Mata IF, Jang Y, Kim CH, Hanna DS, Dorschner MO, Samii A, Agarwal P, Roberts JW, Klepitskaya O, Shprecher DR, Chung KA, Factor SA, Espay AJ, Revilla FJ, Higgins DS, Litvan I, Leverenz JB, Yearout D, Inca-Martinez M, Martinez E, Thompson TR, Cholerton BA, Hu SC, Edwards KL, Kim KS, Zabetian CP.

Mol Neurodegener. 2015 Sep 24;10:50. doi: 10.1186/s13024-015-0045-4.

45.

NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.

O'Brien CF, Jimenez R, Hauser RA, Factor SA, Burke J, Mandri D, Castro-Gayol JC.

Mov Disord. 2015 Oct;30(12):1681-7. doi: 10.1002/mds.26330. Epub 2015 Sep 8.

46.

GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease.

Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, Van Deerlin VM, Ritz B, Rausch R, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson-Hiller AL, Goldman JG, Stebbins GT, Bernard B, Espay AJ, Revilla FJ, Devoto J, Rosenthal LS, Dawson TM, Albert MS, Tsuang D, Huston H, Yearout D, Hu SC, Cholerton BA, Montine TJ, Edwards KL, Zabetian CP.

Mov Disord. 2016 Jan;31(1):95-102. doi: 10.1002/mds.26359. Epub 2015 Aug 21.

47.

Movement disorders emergencies.

Munhoz RP, Scorr LM, Factor SA.

Curr Opin Neurol. 2015 Aug;28(4):406-12. doi: 10.1097/WCO.0000000000000212. Review.

PMID:
26110802
48.

Association of cognitive domains with postural instability/gait disturbance in Parkinson's disease.

Kelly VE, Johnson CO, McGough EL, Shumway-Cook A, Horak FB, Chung KA, Espay AJ, Revilla FJ, Devoto J, Wood-Siverio C, Factor SA, Cholerton B, Edwards KL, Peterson AL, Quinn JF, Montine TJ, Zabetian CP, Leverenz JB.

Parkinsonism Relat Disord. 2015 Jul;21(7):692-7. doi: 10.1016/j.parkreldis.2015.04.002. Epub 2015 Apr 14.

49.

Cognitive profile of LRRK2-related Parkinson's disease.

Srivatsal S, Cholerton B, Leverenz JB, Wszolek ZK, Uitti RJ, Dickson DW, Weintraub D, Trojanowski JQ, Van Deerlin VM, Quinn JF, Chung KA, Peterson AL, Factor SA, Wood-Siverio C, Goldman JG, Stebbins GT, Bernard B, Ritz B, Rausch R, Espay AJ, Revilla FJ, Devoto J, Rosenthal LS, Dawson TM, Albert MS, Mata IF, Hu SC, Montine KS, Johnson C, Montine TJ, Edwards KL, Zhang J, Zabetian CP.

Mov Disord. 2015 Apr 15;30(5):728-33. doi: 10.1002/mds.26161. Epub 2015 Feb 4.

50.

Sleep correlates of trait executive function and memory in Parkinson's disease.

Scullin MK, Fairley JA, Trotti LM, Goldstein FC, Factor SA, Bliwise DL.

J Parkinsons Dis. 2015;5(1):49-54. doi: 10.3233/JPD-140475.

PMID:
25588355

Supplemental Content

Loading ...
Support Center